Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Radiosurgery × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Brain Neoplasms 118 Carcinoma, Non-Small-Cell Lung 112 Prostatic Neoplasms 101 Neoplasm Metastasis 83 Lung Neoplasms 64 Pancreatic Neoplasms 61 Carcinoma, Hepatocellular 58 Breast Neoplasms 45 Melanoma 43 Carcinoma, Renal Cell 32 Neoplasms 31 Colorectal Neoplasms 24 Glioblastoma 23 Squamous Cell Carcinoma of Head and Neck 19 Liver Neoplasms 16 Head and Neck Neoplasms 14 Small Cell Lung Carcinoma 13 Sarcoma 12 Kidney Neoplasms 12 Glioma 11 Recurrence 9 Urinary Bladder Neoplasms 8 Gliosarcoma 7 Central Nervous System Neoplasms 7 Adenocarcinoma 7 Radiation Injuries 6 Prostate Cancer Metastatic 6 Ovarian Neoplasms 6 Neuroma, Acoustic 6 Meningioma 6

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡